Key Takeaways
- • Fathom Therapeutics closed an oversubscribed $47 million Series A financing round led by Sutter Hill Ventures, with participation from Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures.
- • The company's proprietary drug design engine, Microcosmos, uses quantum chemistry and AI to simulate protein dynamics at atomic resolution, accelerating modeling by 10,000x without sacrificing accuracy compared to traditional methods.
- • Fathom's physics-based generative design platform addresses a critical limitation in current drug discovery: the reliance on static protein structures, enabling the company to design molecules targeting previously "undruggable" proteins.
- • The company appointed a new Chief Business Officer, added an independent board member, and established a Scientific Advisory Board as part of the financing, signaling operational expansion.
- • Microcosmos has demonstrated early momentum across multiple target classes and small molecule modalities, with at least one successful application generating novel degraders against challenging targets.
Summary
Fathom Therapeutics, formerly Atommap Corp., announced a $47 million oversubscribed Series A financing round on April 27, 2026, marking a significant milestone for the New York-based drug discovery platform company. The round was led by Sutter Hill Ventures, with additional investment from Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures, among other participants. The oversubscribed status reflects strong institutional confidence in the company's technology platform and market opportunity.
The company's core technology, Microcosmos, represents a fundamental shift in computational drug discovery methodology. Rather than relying on static protein structures—the traditional approach in early-stage drug design—Microcosmos simulates protein motion at atomic resolution using proprietary algorithms based on quantum mechanical principles. The platform accelerates protein dynamics modeling by 10,000x without compromising accuracy, generating previously difficult-to-capture data on dynamic protein behavior that can be translated into measurable cellular outcomes. This physics-based approach enables the generative design of small molecules capable of reshaping protein behavior for targeted therapeutic effects.
According to Co-Founder and CEO Huafeng Xu, PhD, the technology overcomes a critical bottleneck in contemporary drug discovery: "Current drug discovery efforts are limited by reliance on static structures of isolated proteins. Microcosmos is a world model of drugs in living cells that surpasses these limitations by translating accurate quantum mechanical calculations to measurable cellular outcomes." Early validation of this approach includes successful identification of novel degraders targeting an "undruggable" protein, a class of targets traditionally considered intractable to small molecule intervention.
The financing round coincides with organizational expansion, including the appointment of a new Chief Business Officer, the addition of an independent board member, and the establishment of a Scientific Advisory Board. These moves suggest Fathom is scaling operations to translate early computational success into clinical development pipelines across multiple therapeutic modalities and target classes.
The company's core technology, Microcosmos, represents a fundamental shift in computational drug discovery methodology. Rather than relying on static protein structures—the traditional approach in early-stage drug design—Microcosmos simulates protein motion at atomic resolution using proprietary algorithms based on quantum mechanical principles. The platform accelerates protein dynamics modeling by 10,000x without compromising accuracy, generating previously difficult-to-capture data on dynamic protein behavior that can be translated into measurable cellular outcomes. This physics-based approach enables the generative design of small molecules capable of reshaping protein behavior for targeted therapeutic effects.
According to Co-Founder and CEO Huafeng Xu, PhD, the technology overcomes a critical bottleneck in contemporary drug discovery: "Current drug discovery efforts are limited by reliance on static structures of isolated proteins. Microcosmos is a world model of drugs in living cells that surpasses these limitations by translating accurate quantum mechanical calculations to measurable cellular outcomes." Early validation of this approach includes successful identification of novel degraders targeting an "undruggable" protein, a class of targets traditionally considered intractable to small molecule intervention.
The financing round coincides with organizational expansion, including the appointment of a new Chief Business Officer, the addition of an independent board member, and the establishment of a Scientific Advisory Board. These moves suggest Fathom is scaling operations to translate early computational success into clinical development pipelines across multiple therapeutic modalities and target classes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.